Does Viibryd Help Anxiety?
Yes, Viibryd (vilazodone) can help anxiety, particularly generalized anxiety disorder (GAD), though it is not a first-line treatment and should be considered after SSRIs have been tried.
Evidence for Anxiety Treatment
Vilazodone is classified as an SSRI with additional 5-HT1A receptor partial agonist properties 1. While it is FDA-approved only for major depressive disorder in adults 2, multiple randomized controlled trials have demonstrated efficacy for GAD:
- Three well-designed RCTs showed vilazodone (20-40 mg daily, mean dose 31.42 mg) was significantly superior to placebo for GAD symptoms, with statistical significance (p<0.001) on primary anxiety measures 3, 4, 5, 6
- Effect size is modest: Number needed to treat (NNT) = 10 for response on Hamilton Anxiety Rating Scale, meaning 10 patients need to be treated for one additional patient to respond compared to placebo 3
- Functional improvement: Vilazodone showed significant improvement on the Sheehan Disability Scale in some trials 5
Clinical Context and Positioning
Vilazodone should be considered a second- or third-line option for anxiety disorders, not first-line 7. Here's why:
First-Line Treatments Remain Standard SSRIs
The 2020 AACAP guidelines clearly state that SSRIs as a class (fluoxetine, fluvoxamine, paroxetine, sertraline, escitalopram, citalopram) are the recommended first-line pharmacotherapy for anxiety disorders including GAD, social anxiety, separation anxiety, and panic disorder 1. Vilazodone is mentioned as part of the SSRI class but was not included in the primary evidence review that established SSRI efficacy.
Why Not First-Line?
- Tolerability concerns: Likelihood to be helped versus harmed was inconclusive [1.4 (0.48,3.33)] 3
- High discontinuation rate: NNH = 14 for discontinuation due to adverse effects, primarily nausea and diarrhea 3
- Adverse event burden: 83% of vilazodone-treated patients experienced adverse events versus 60% on placebo 4
- Lack of comparative data: No head-to-head trials comparing vilazodone to established first-line SSRIs for anxiety 7
Specific Anxiety Contexts
Anxious Depression
Vilazodone may have particular utility in patients with major depression accompanied by anxiety symptoms 8:
- 82% of MDD patients in pooled trials had anxious depression
- Significant improvements on Hamilton Anxiety Rating Scale (difference -1.82, p<0.001) and HAMD17 Anxiety/Somatization subscale (difference -0.75, p<0.001)
- Effective for both psychic and somatic anxiety symptoms in depression 8
Generalized Anxiety Disorder
For primary GAD without depression, vilazodone showed efficacy but with caveats 4, 5, 6:
- Dose matters: 40 mg/day was effective; 20 mg/day did not separate from placebo in fixed-dose trials 6
- Completion rates: Only 71-77% completed 8-week trials on vilazodone versus 81% on placebo 4, 5
Practical Prescribing Algorithm
When to Consider Vilazodone for Anxiety:
After SSRI trial failure: Patient has tried at least one standard SSRI (sertraline, escitalopram, fluoxetine) at adequate dose for 6-8 weeks without response
Comorbid depression with anxiety: Patient has MDD with prominent anxiety symptoms where treating both conditions is priority 8
SNRI alternative: Consider alongside SNRIs (venlafaxine, duloxetine) as second-line options 1
Dosing Strategy:
- Start 10 mg daily with food for 7 days, then increase to 20 mg daily 2
- Target dose: 40 mg daily (most effective dose for GAD) 6
- Must take with food to ensure adequate absorption 2
Critical Safety Considerations
Common Adverse Effects (≥5% and twice placebo rate):
- Nausea (most common, often improves after first weeks)
- Diarrhea
- Dizziness
- Fatigue
- Sexual dysfunction (delayed ejaculation, erectile dysfunction) 2, 5
Serious Risks:
- Suicidal ideation: Black box warning for patients ≤24 years old 2. However, post-hoc analysis showed no increased risk in adults with MDD or GAD 9
- Serotonin syndrome: Avoid MAOIs, use caution with other serotonergics 2
- Discontinuation syndrome: Taper slowly; do not stop abruptly 2
Monitoring:
- Close follow-up during first 4-8 weeks for suicidal ideation, especially in younger adults
- Assess tolerability at 1-2 weeks (nausea peak)
- Evaluate efficacy at 6-8 weeks minimum
Bottom Line
Vilazodone is effective for anxiety but not optimal as first-line therapy. Use it when standard SSRIs have failed or when treating comorbid anxious depression. The dual mechanism (SSRI + 5-HT1A partial agonist) has not been proven superior to standard SSRIs in clinical practice 10, 7, and the higher adverse event burden limits its utility. Start with proven first-line SSRIs (sertraline, escitalopram) for anxiety disorders, reserving vilazodone for second-line use or specific clinical scenarios where its profile may offer advantages.